ConductScience.org, home

Trial · NCT02374593

Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism

NCT02374593, Not applicable, Completed, Erica Eugster; results first posted 2017-10-09

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism. Trials, record NCT02374593. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02374593

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism
NCT number
NCT02374593
Status
Completed
Phases
Not applicable
Enrollment
24 participants, actual
Lead sponsor
Erica Eugster
Conditions
Congenital Hypothyroidism
Interventions
Levothyroxine, Ultrasound
First posted
2015-03-02
Last updated
2017-10-09
Results first posted
2017-10-09

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryDose Adjustments6 months
Thyroid labs (TSH and fT4/T4) will be monitored per standard care: 2 weeks after initiation of levothyroxine and once monthly during the first 6 months of treatment. The number of dose adjustments required per participant during the first 6 months of treatment were recorded.
SecondaryNumber of Adjustments Due to Overtreatment in Subjects With Athyreosis, Ectopic and Eutopic Thyroid Glands Compared With Controls6 monthsWhether the dose adjustment was made for overtreatment was noted as based on TSH and fT4/T4 results

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYDose Adjustments6 monthsNumber of dose adjustmentsMEAN
SECONDARYNumber of Adjustments Due to Overtreatment in Subjects With Athyreosis, Ectopic and Eutopic Thyroid Glands Compared With Controls6 monthsdose adjustmentsMEAN

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Dose AdjustmentsTargeted Dosing2.5Standard Error 0.334Number of dose adjustments
Dose AdjustmentsHistorical Control2.4Standard Error 0.211Number of dose adjustments
Number of Adjustments Due to Overtreatment in Subjects With Athyreosis, Ectopic and Eutopic Thyroid Glands Compared With ControlsPatients With Athyreosis2.7Standard Error 0.275dose adjustments
Number of Adjustments Due to Overtreatment in Subjects With Athyreosis, Ectopic and Eutopic Thyroid Glands Compared With ControlsPatients With Dysgenetic Thyroids2Standard Error 0.275dose adjustments
Number of Adjustments Due to Overtreatment in Subjects With Athyreosis, Ectopic and Eutopic Thyroid Glands Compared With ControlsPatients With Eutopic Thyroids1Standard Error 0.275dose adjustments
Number of Adjustments Due to Overtreatment in Subjects With Athyreosis, Ectopic and Eutopic Thyroid Glands Compared With ControlsHistorical Controls2Standard Error 0.275dose adjustments

Participant flow6

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDTargeted Dosing24
Overall StudySTARTEDHistorical Control44
Overall StudyCOMPLETEDTargeted Dosing22
Overall StudyCOMPLETEDHistorical Control44
Overall StudyNOT COMPLETEDTargeted Dosing2
Overall StudyNOT COMPLETEDHistorical Control0

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

TotalGroupAffectedAt risk
Total, all-cause mortalityTargeted Dosing
Total, all-cause mortalityHistorical Control
Total, other adverse eventsTargeted Dosing00
Total, other adverse eventsHistorical Control00
Total, serious adverse eventsTargeted Dosing00
Total, serious adverse eventsHistorical Control00

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02374593

GET https://conductscience.org/api/trials/v1/NCT02374593/registered